By Johnathan Nieves
Lower back pain is the fifth leading cause for doctor visits in the U.S. and over 85 percent of people suffer at least one bout of lower back pain in their lifetime. SOMA®, a new drug under development by, Meda Pharmaceuticals, Inc., a Somerset, N.J. based company, has been shown to improve functionality and reduce disability associated with lower back pain in as few as three days as confirmed by patient outcomes data.
The “outcomes data differentiates SOMA® 250 mg among the diverse treatment choices for patients with acute low back pain,” said Steven M. Simon, MD, RPh, Clinical Assistant Professor at the University of Kansas School of Medicine and Biosciences.
“Almost all acute low back pain is mechanical in origin and one in five patients with this condition suffers from significant limitations in activity. Treatment of acute low back pain with SOMA® 250 mg has been shown to improve functionality, as measured by an internationally validated tool.”
Meda Pharmaceuticals, Inc. claims that SOMA® is the only skeletal muscle relaxant proven to significantly improve functionality in patients with acute low back pain as measured by the Roland-Morris Disability Questionnaire (RMDQ), an internationally validated standard for measuring the degree of disability and functionality in patients with lower back pain.
The Company’s approach to assessing patient symptom progression during SOMA® treatment via the RMDQ is unique in that it is a form of outcomes-based healthcare. Outcomes-based health care has become an increasingly popular and comprehensive approach to healthcare with goals of providing high quality care and reducing treatment costs.
“Overall, the greatest cost savings from a societal perspective may be obtained from interventions that promote early return to work and minimize lost productivity,” said Al Moorad, MD, Medical Director, Integris Jim Thorpe Rehabilitation, Oklahoma City. “This may be accomplished by appropriate drug utilization to allow patients to actively participate in rehabilitation therapy and return to daily activities.”
Meda Pharmaceuticals’ will present its findings this week at the 26th annual meeting of the American Academy of Pain Medicine in San Antonio, TX.